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Abstract
Background: We report on the case of an established perinuclear antineutrophil cytoplasmic antibody (pANCA)
associated renal vasculitis being treated with prednisolone and rituximab, where the patient presented with leg
weakness, urinary and faecal incontinence and buttock pain consistent with transverse myelitis.
Case presentation: The patient underwent MRI scanning showing patchy cord enhancement from T10 to the
conus, which was suggestive of a cord malignancy. Prior to a cord biopsy, he was treated with steroids and a
repeat MRI showed resolution of the original lesion with a new similar lesion from C7 to T3.
Conclusions: He made a marked recovery after further treatment with high dose steroids and plasma exchange.
Background
This case report highlights a possible presentation of
spinal cord inflammation in which imaging initially sug-
gested an alternative pathology to transverse myelitis,
such as a spinal cord tumour. In addition it examines
recurrent myelitis associated with a systemic pANCA
associated vasculitis despite active immunosuppression,
in particular the failure of rituximab and the require-
ment for plasma exchange.
There are a handful of reports of central nervous sys-
tem involvement in patients with vasculitis. Many of
these specifically involve Wegener’s granulomatosis;
López-Rodríguez et al [1] report on a case of Wegener’s
with a granulomatous mass in the Meckel cavum and
diffuse meningeal involvement, treated with steroids and
cyclophosphamide. Levin et al[2] report on a case of
Wegener’s granulomatosis with dural inflammation
managed with steroids and cyclophosphamide. Their
case highlights periaortitis as a particular feature.
N a g a s h i m ae ta l [ 3 ]r e p o r to nac a s eo fp A N C AW e g e -
ner’s with hypertrophic pachymeningitis and multiple
cranial neuropathies, this case similarly presented with
an initial diagnosis suggesting malignancy that was dis-
proved at biopsy.
Morinaga et al[4] report on a case of pANCA positiv-
ity associated with cerebellar dural enhancement as well
as temporal arteritis. This patient had multiple cranial
neuropathies.
The imaging features initially supporting a diagnosis
of a cord tumour have been documented in the litera-
ture by Rourke et al[5]. In this case the abnormal area
was macroscopically normal and intraoperative speci-
mens did not show neoplastic cells, and the patient
recovered with cyclophosphamide and steroids.
Rituximab, the chimeric anti-CD20 antibody was used
in the treatment of this patient. Lovric et al[6] reported
on a case series using rituximab as rescue therapy in
ANCA positive vasculitis. Remission, whether partial or
complete, was achieved in 14/15 patients. Rituximab has
been used to treat neuromyelitis optica[7], and in our
case although imaging features were consistent, there
was no optic neuritis, a negative antibody to aquaporin-
4 and poor response to rituximab.
Zandman-Goddard et al report on a patient with
hepatitis C and persistent ANCA positivity[8]. Our
patient tested negative for hepatitis C infection.
Our case highlights firstly t h ep o s s i b i l i t yo fas e r i o u s
central nervous system flare despite rituximab therapy,
where the presentation imaging suggested an alternative
pathology, which was successfully treated with an
increased steroid dose and plasma exchange.
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A 65-year-old man presented in February 2007 with
deteriorating renal function, creatinine 208 μmol/L
(reference range 60-120 μmol/L). His background
included chronic obstructive pulmonary disease and
radiologically diagnosed asbestosis, previous duodenitis
and pericarditis in 1970. His regular medications
included a statin, a proton pump inhibitor, aspirin and
an antimuscarinic bronchodilator.
His urinalysis showed protein 1+, blood 4+ and his
serum immunology showed a positive pANCA and mye-
loperoxidase (MPO) antibody. His C-reactive protein
(CRP) was 33 mg/L. He underwent renal biopsy which
showed evidence of an inactive vasculitis; 25 glomeruli
(11 normal, 7 sclerosed, 7 showing fibrous crescents, 0
showing cellular crescents). There was patchy tubular
atrophy, focal secondary interstitial inflammation and
fibrosis. Immunofluoresence was negative. Silver stain
was unremarkable. This was all in keeping with a
pANCA-associated renal vasculitis that was currently
quiescent.
He maintained a stable creatinine with CRP <8 mg/L
and was managed conservatively with close monitoring.
In November 2007 it was noted he had a rising creati-
nine reaching 309 μmol/L prompting the initiation of
prednisolone 80 mg and cyclophosphamide 200 mg with
co-trimoxazole prophylaxis.
His creatinine fell to 146 μmol/L by April 2008 with
this regimen and his prednisolone was slowly weaned.
Cyclophosphamide was discontinued due to leucopaenia
seven weeks after commencement and this was replaced
with azathioprine 150 mg.
In July 2008 he had lower respiratory tract symptoms
with raised inflammatory markers and was suspected of
having active pulmonary involvement of his vasculitis.
He underwent high resolution CT scanning of the chest
which demonstrated areas of sub-pleural reticular sha-
dowing, many related to areas of pleural thickening. He
was noted to have a marked reduction in gas transfer
(to 30% predicted), as well as a restrictive defect on
spirometry. His azathioprine was changed to mycophe-
nolate mofetil (MMF) 1 g bd as his CRP remained ele-
vated (at 24 mg/L) with continued clinical vasculitic
activity.
By September 2008 his creatinine rose to 198 μmol/L
with continued pANCA positivity and his CRP was ele-
vated at 60 mg/L. In view of cyclophosphamide induced
leucopaenia and failure of control with MMF, he was
commenced on Rituximab 375 mg/m
2 weekly for four
weeks. At this stage his prednisolone dose was 25 mg.
In November 2008 he presented to his general practi-
tioner with a three-week history of progressive weakness
of the left leg and sensory loss up to T10 dermatome
level followed by urinary and faecal retention. He com-
plained of buttock pain and also some similar right-
sided symptoms, which was consistent with a clinical
diagnosis of transverse myelitis. There was no optic
involvement. He was referred to the Spinal team who
requested an MRI (Figures 1 &2) demonstrating patchy,
slightly nodular central enhancement at T10 extending
to the conus. MRI head was normal. The radiological
differential diagnosis included a primary cord neoplasm
such as astrocytoma or less likely ependymoma.
He was referred to the Neurologists and underwent
CT scanning of the chest, abdomen and pelvis. This
confirmed no primary malignancy or evidence of meta-
static disease. He underwent CSF examination showing
10 × 10
6/l lymphocytes with no malignant cells, protein
of 0.9 g/L. An antibody to aquaporin-4 was negative, as
was lupus and antiphospholipid serology.
He was referred for biopsy of the cord lesion. However,
he had a boost in his dose of steroids and it was sug-
gested to repeat the MRI scan before cord biopsy. The
repeat MRI (Figures 1 &2) showed that the large lesion
involving the lower thoracic cord had now almost com-
pletely resolved and the area of enhancement seen in the
lower cord was no longer present. There was a new
lesion extending from C7 down to T3. This was similar
to the original lesion in that it was expansile and returned
high signal on T2 weighted images with a much smaller
area of central ring enhancement. It was felt that these
changes made malignancy seem extremely unlikely as the
affected areas had changed with time and increased
immunosuppression. Vasculitis was suggested as a unify-
ing diagnosis for his symptoms, the increase in steroids
explaining the drastic MRI changes. His CRP peaked at
137 mg/L and dropped to 7 mg/L. Hence cord biopsy
was not undertaken and his steroids continued at high
dose, MMF stopped and rituximab continued. He was
discharged and a further outpatient MRI showed contin-
ued improvement and his steroids were weaned down.
In May 2009 he returned to hospital following further
left sided pain. He was treated for a vasculitis flare. He
underwent repeat MRI head and spine. This showed a
single high focus in the right cerebellar hemisphere. He
was treated with intravenous methylprednisolone and
further rituximab treatment was arranged. His last dose
of rituximab was December 2009.
In February 2010 he was again admitted with left
sided pain and a CRP of over 300 mg/L. There was no
evidence of infection and his MRI was repeated which
did not show any abnormal high signal on this occasion.
His steroids were again increased. He was recommenced
on MMF, which then had to be stopped owing to
increased frequency of chest infections. He was noted to
be Cushingoid as a result of prolonged steroid therapy.
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Page 2 of 4Figure 1 Chronological MRI images of lumbar spine - November 2008/December 2008/May 2009. In figure 1 the lumbar spine is most
clearly affected in the first image (November 2008). The images show increased signal within the substance of the spinal cord during episodes
of active vasculitis, with some subtle expansion of the cord.
Figure 2 Chronological MRI images of thoracic spine - November 2008/December 2008/May 2009. In figure 2 the thoracic spine is most
clearly affected in the second image (December 2008). The images show increased signal within the substance of the spinal cord during
episodes of active vasculitis, with some subtle expansion of the cord.
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Page 3 of 4In May 2010 he was commenced on plasma exchange
which, after seven exchanges, successfully treated
ongoing symptoms of leg pain attributed to spinal vas-
culitis and brought his CRP to below 3 mg/L. Plasma
exchange is being continued at present due to continued
pANCA positivity.
Conclusions
The case presented highlights the difficulties in diagno-
sis, management and complications of vasculitis.
In the context of an established diagnosis of vasculitis,
progression and extra-renal features were complicated
by varying appearances on spinal MRI imaging, initially
thought to be tumour. There were radical changes on
subsequent images which led to questioning of the origi-
nal diagnosis of spinal cord malignancy.
Finally the condition was resistant to rituximab but
responded to high-dose steroids and then plasma
exchange.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompany-
ing images. A copy of the written consent is available
for review by the Editor-in-Chief of this journal.
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